Corcept Therapeutics Inc
CORT
Market Cap$7.57B
Close$
$201.14
162% upside
Current Fair Value
162% upsideUndervalued by 162% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.57 Billion |
|---|---|
| Enterprise Value | $7.50 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $1.35 |
| Beta | 0.18 |
| Outstanding Shares | 104,106,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 55.93 |
|---|---|
| PEG | -207.76 |
| Price to Sales | 12.8 |
| Price to Book Ratio | 12.8 |
| Enterprise Value to Revenue | 10.94 |
| Enterprise Value to EBIT | 67.65 |
| Enterprise Value to Net Income | 56 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...